Pricing on Lab supply sourced Hesperetin (Google Gemini Pro “Thinking Mode”):
Prices are calculated per milligram (mg) based on the smallest or most common standard catalog unit.
The pricing table below includes the updated bulk package options for Cayman Chemical, showing a clear volume discount curve where the price per milligram drops significantly as package size increases.
Hesperetin Aglycone (CAS 520-33-2) Pricing Data
Supplier
Grade
Common Unit
Unit Price (USD)
Price per mg
1. Cayman Chemical
Research
500 g
$801.00
$0.00160
2. Cayman Chemical
Research
100 g
$195.00
$0.00195
3. Cayman Chemical
Research
50 g
$104.00
$0.00208
4. Cayman Chemical
Research
25 g
$55.00
$0.00220
5. Glentham Life Sciences
Fine Chem
10 g
$28.00
$0.00280
6. BOC Sciences
Bulk
50 g
$159.00
$0.00318
7. AK Scientific (AKSci)
Fine Chem
5 g
$16.00
$0.00320
8. Fluorochem
Fine Chem
5 g
$25.00
$0.00500
9. Ambeed
Fine Chem
1 g
$6.00
$0.00600
10. TCI Chemicals
Fine Chem
5 g
$31.25
$0.00625
11. Sigma-Aldrich
Analytical
1 g
$29.32
$0.02932
12. FUJIFILM Wako
Research
1 g
$58.00
$0.05800
13. Spectrum Chemical
Reagent
5 g
$373.00
$0.07460
14. TRC (Toronto Research)
Standard
1 g
$175.00
$0.17500
15. TargetMol
Bioactive
100 mg
$64.00
$0.64000
16. ChemScene
Research
100 mg
$70.00
$0.70000
17. MedChemExpress
Bioactive
100 mg
$80.00
$0.80000
18. AdooQ Bioscience
Bioactive
100 mg
$80.00
$0.80000
19. Abcam
Research
100 mg
$110.00
$1.10000
20. APExBIO
Bioactive
50 mg
$58.00
$1.16000
21. Santa Cruz Biotech
Research
100 mg
$145.00
$1.45000
22. Biozol
Analytical
100 mg
$215.00
$2.15000
23. Selleckchem
Bioactive
10 mg
$40.00
$4.00000
Technical Observations & Longevity Context
Hesperetin vs. Hesperidin: For longevity applications targeting the senolytic or AMPK-activation pathways, pure Hesperetin (the aglycone) is often preferred due to its superior bioavailability compared to Hesperidin (the rutinoside). The glycosidic bond in hesperidin must be cleaved by gut microbiota (e.g., Bacteroides uniformis), making the aglycone a more direct intervention.
Knowledge Gap: While Hesperetin is a potent antioxidant and potential senotherapeutic, human clinical data specifically using high-dose pure aglycone for longevity is sparse. Most studies utilize citrus extracts (Hesperidin).
Data Requirement: Full pharmacokinetic profiling of the aglycone vs. the glycoside in humans is needed to determine the optimal “longevity dose” and whether the localized gut conversion of the glycoside offers specific microbiome-mediated benefits that the aglycone might bypass.
Collaborative Truth-Seeking: Prices for “Bioactive” compounds from vendors like Selleckchem or APExBIO are highly inflated because they guarantee high HPLC purity and “ready-to-use” sterile packaging for cell culture. For self-experimentation or pilot biotech ventures, sourcing from Cayman or AKSci provides a 100x–1,000x cost advantage while maintaining >97% purity.
No, Naringenin is not a direct substitute for Hesperetin regarding the specific “longevity gene” (CISD2) mechanism described in the skin aging paper.
While they are molecular cousins (both are citrus flavanones) and share some general benefits like lowering inflammation, they act on completely different cellular switches to achieve their anti-aging effects.
Here is the technical breakdown of why they are different tools for different jobs:
1. The Critical Difference: The “Master Switch”
Hesperetin (The CISD2 Specialist):
Mechanism: It is a rare, direct activator of CISD2 (CDGSH iron-sulfur domain-containing protein 2). This is the specific pathway identified in your paper that restores mitochondrial integrity and “reverses” skin aging.
Outcome: Stabilizes the outer mitochondrial membrane, preventing the “leaky” mitochondria that drive senescence.
Naringenin (The Metabolic Specialist):
Mechanism: It primarily activates AMPK (the metabolic sensor) and SIRT1/SIRT3 (sirtuins). It also modulates PPARα (lipid metabolism), which Hesperetin does not effectively touch.
Outcome: Mimics fasting/exercise, burns fat, and improves glucose handling, but does not activate the CISD2 longevity gene.
2. Comparative Analysis: Hesperetin vs. Naringenin
Feature
Hesperetin (Aglycone)
Naringenin (Aglycone)
Primary Target
CISD2 (Longevity/Mitochondria Integrity)
AMPK & PPARα (Metabolism/Fat Burning)
Skin Mechanism
Reverses intrinsic aging by restoring collagen production via CISD2.
Protects against UV damage (Photoaging) by inhibiting NF-κB (inflammation) and IGFBP3.
Senolytic Effect
Senomorphic: Suppresses SASP (zombie cell secretions) by fixing mitochondria.
Pro-Autophagic: Encourages cells to eat their own waste (autophagy) via AMPK.
High Risk: Inhibits CYP3A4 (Conflicts with Rapamycin/Statins).
High Risk: Also inhibits CYP3A4 and P-gp (Similar conflicts).
3. The “Stacking” Strategy
Since they hit different pathways, they are synergistic, not redundant.
If you want the skin/lifespan results from the paper: You must use Hesperetin. Naringenin will not flip the CISD2 switch.
If you want a metabolic foundation: Naringenin is superior for metabolic syndrome and visceral fat reduction.
Biohacker Verdict: Do not swap them. If your goal is the specific rejuvenation described in the study, Naringenin is a “fail” as a substitute. However, taking both (e.g., via a full-spectrum citrus bioflavonoid complex that is standardized for both aglycones) would theoretically cover both mitochondrial stability (CISD2) and metabolic cleanup (AMPK).
Warning: Both compounds are potent CYP3A4 inhibitors (the “Grapefruit Juice Effect”). If you stack them, you are doubling down on liver enzyme inhibition. Do not take this stack if you are on Rapamycin, blood thinners, or heart medication without strict medical monitoring.
Hesperetin is a metabolite of hesperidin. Intestinal bacteria convert hesperidin to hesperetin, which is then absorbed. So it’s not a matter of increasing absorption of hesperidin. Researchers recommend taking a good multistrain probiotic when taking hesperidin.
Intestinal bacteria are not the only pathway to convert Hesperidin to Hesperitin, the liver can do it as well. The key importance of gut bacteria is that without them Hesperidin has a bioavailability (gut absorption) of below 5%, while Hesperitin has a bioavailability of 20%.
However if you take Lipo Hesperidin, 95% of it is absorbed (bound to Lipo) and the Hesperidin is slowly released in the blood over 24 hours and then converted by the Liver, first to Hesperitin, then other active downstream metabolites.
No, but I am not good test case since I stopped taking both Collagen (due to poor taste of the Bovine collagen I was using in my coffee) and 17alpha-Estradiol about a year ago and my skin is noticeable more wrinkly and dry.
I found a better Collagen (liquid Collagen from Cosco and a powdered drink from Renue that also includes Taurine and electrolytes that both taste good) and am restarting along with 17alpha-Estradiol to try to reverse my skin aging.
I’m not so sure this is accurate. I asked Gemini to evaluate the science and clinical evidence for the above statement, and this is what it had to say: (Note: I also tried ChatGPT and it said the same thing).
The statement contains a critical biological error regarding how the human body processes these compounds. While the bioavailability numbers are directionally correct (aglycones are better absorbed than glycosides), the proposed “liver conversion” mechanism for Liposomal Hesperidin is scientifically flawed.
Here is the breakdown of the claims vs. the biology.
1. The “Liver Conversion” Myth
Claim:“Intestinal bacteria are not the only pathway… the liver can do it as well.”Verdict: FALSE
The Biology: Hesperidin is a Rutinoside . This means the flavonoid (Hesperetin) is bound to a two-part sugar: Glucose + Rhamnose. To “activate” the molecule, you must cut off this sugar chain.
The Problem: Human liver cells (and human cells in general) do not possess the enzyme α-L-rhamnosidase. This enzyme is required to cut off the Rhamnose sugar.
The Reality: Only specific gut bacteria (e.g., Bifidobacterium, Lactobacillus) possess this enzyme. If you bypass the gut bacteria (e.g., by injecting Hesperidin or using a delivery system that prevents bacterial contact), the Hesperidin remains a glycoside. The human liver cannot “unlock” it. It will circulate as the inactive glycoside and be excreted by the kidneys.
2. Bioavailability Stats
Claim:“Hesperidin <5% vs Hesperetin 20%.”Verdict: PLAUSIBLE
Hesperidin (<5%): Accurate. Without specialized processing, standard Hesperidin has very poor solubility and relies entirely on the gut microbiome for conversion, leading to highly variable and low absorption.
Hesperetin (~20%): Plausible. The aglycone (Hesperetin) bypasses the need for bacterial cleavage and is absorbed directly in the small intestine, though its absolute bioavailability is still limited by Phase II metabolism (rapid glucuronidation).
3. The Liposomal Paradox
Claim:“Lipo Hesperidin… is absorbed… then converted by the Liver.”Verdict: BIOLOGICALLY INCOHERENT
The Trap: If you use a Liposome to sneak intact Hesperidin (the glycoside) into the bloodstream, you have effectively “smuggled a locked safe into the bank, but you left the key (bacteria) outside.”
The Outcome: Since the liver lacks the rhamnosidase “key,” the high levels of Hesperidin circulating in the blood cannot be converted to the active Hesperetin.
The Fix: A properly formulated liposomal product for longevity must use Liposomal Hesperetin (the Aglycone), not Hesperidin. If the label says “Liposomal Hesperidin,” you are paying a premium for a molecule your body might not be able to activate efficiently.
Corrected Science for Your Records
"Intestinal bacteria are the sole effective pathway to convert Hesperidin to Hesperetin because humans lack the α-L-rhamnosidase enzyme.
Standard Hesperidin has poor bioavailability (<5%) because it depends on this bacterial conversion.
Liposomal Hesperetin (Aglycone) is the superior choice. It is 95% absorbed and—crucially—is already in the active form, meaning it does not require bacterial processing or liver conversion to work. Liposomal Hesperidin (Glycoside) should be avoided as it bypasses the necessary bacterial activation."
I am puzzled since Google AI (which supposedly is based on Gemini) has this answer to the question “How is Liposomal Hesperidin absorbed in the body”:
Liposomal Hesperidin enhances the poor oral bioavailability of standard hesperidin (roughly 20%) by encapsulating the compound in lipid vesicles, allowing it to bypass some of the initial digestive breakdown in the stomach. This formulation protects the hesperidin, facilitating better absorption in the small intestine, providing a slower, more sustained release into the bloodstream.
Key Absorption Mechanisms:
Liposomal Encapsulation: The phospholipid bilayer of the liposome protects the hesperidin, enhancing its stability and solubility compared to non-encapsulated forms.
Small Intestine Absorption: Unlike standard hesperidin, which often relies on colonic microbial breakdown, liposomal formulations increase direct absorption in the small intestine.
Metabolism and Transport: After absorption, the active aglycone form (hesperetin) is formed and metabolized in the liver and intestinal epithelium into glucuronide and sulphate conjugates.
Peak Plasma Concentration: Similar to non-liposomal forms, absorbed hesperetin typically reaches peak plasma concentrations around 5 to 7 hours after ingestion.
Advantages:
Increased Bioavailability: Liposomal encapsulation significantly improves the absorption of this otherwise poorly soluble, hydrophobic flavonoid.
Protection: The liposomes shield the hesperidin from oxidation and degradation.
Note there is no explained mechanism for “Metabolism and Transport: After absoption, the active aglycone form (hesperitin) is formed and metabolized in the liver and intestinal epithelium into glucoronide and sulphase conjugates.”
Is Gemini hallucinating here or in RapaAdmins presentation ?
I’m not sure why the answers would be different. I could imagine that they would (or could justify) putting more compute power / investment into the Gemini Pro service than the free public google search / AI. I’m using only Google Gemini Pro (the $20/month service).
Searching… it seems that the google AI free service is also using an older generation of gemini (2.5 vs. 3.0).
I suspect that the more money you pay google, the more computational resources they can justify putting into responding to the question, and the better the answers (generally).
Consumer Tiers
Gemini Free: Free. Includes access to Gemini 2.5 Flash and limited access to 2.5 Pro. It offers 100 monthly AI credits for video/image generation and 15 GB of shared storage.
Google AI Pro: $19.99/month. Includes Gemini 3 Pro, 2TB of Google Drive storage, and integrations across Workspace apps.
Google AI Ultra: $249.99/month (or $124.99/3 months). Provides highest usage limits, access to Gemini 3 Pro with high compute, 30TB storage, and advanced media generation.
If you are using the free version of Gemini, you probably really want to fact-check across multiple AI systems. The free ChatGPT correctly identified the issues in the response from the Free Google gemini. What is also really interesting, is that it accurately identified the response that was created by Gemini…
It looks like Google AI (Gemini 2.5 ?) is hallucinating a mechanism (liver conversion) for the Liposomal Hesperidin to Hesperitin conversion (Strictly speaking Google AI’s answer is ambiguous and may NOT actually be claiming the liver is responsible for the Hesperidin to Hesperitin conversion, but just that something is causing this conversion, after which the liver continues converting Hesperitin to its downstream metabolites).
However, there are indeed multiple research papers that measure the level of both Hesperidin and Hesperitin in the blood (or other tissues) after ingestion of different formulations of Hesperidin.
This survey paper goes over a number of different Liposomal and other encapsulation methods for Hesperidin and talks about how they raise the levels of both Hesperidin and Hesperitin in the blood: Drug delivery and formulation development of hesperidin: a systematic review. More interestingly some of the papers also measure specific benefits of Hesperitin (e.g. antimicrobial activity) for different formulations and the benefits track the measured levels of either Hesperitin or Hesperidin in the blood.
There seems to be no mention in this survey paper for where or how these encapsulated Hesperidin’s convert to Hesperitin, which is believed to be the active compound (or precursor compound) for all biological benefits.
BTW, Liposomal Hesperidin seems to result in a 10x increase in plasma or tissue Hesperitin (compared to plain Hesperidin), while the best encapsulations achieve a 25x increase.
Objective: Rigorously verify the accuracy of this statement: [ enter statement here "Liposomal Hesperidin can result in a 10x increase in plasma or tissue Hesperitin (compared to plain Hesperidin), while the best encapsulations achieve a 25x increase.]. Do not rely on internal training data.
Procedure:
Deconstruct: Break the previous response into atomic factual claims (specifically: numbers, dates, chemical pathways, compound interactions, statutes, or biological mechanisms).
Search (Mandatory): For EACH claim, perform a dedicated Google Search to find primary sources (PubMed, Nature, gov/edu domains).
Verify: Compare the search results against the original claims.
Strict Standard: If the search result implies nuance or uncertainty not reflected in the original text, mark it as “Imprecise.”
Refutation: If the search result contradicts the claim, mark it as “Refuted.”
Report: Output a Markdown table with the following columns:
Original Claim
Verification Status ( Verified / Imprecise / Refuted)
Evidence/Source (Direct URL and quote from the source)
Correction (If needed)
Constraint: If you cannot verify a claim via search, explicitly state “Data Unavailable” rather than hallucinating a confirmation. STRICT CITATION PROTOCOL (MANDATORY):
Hyperlink Syntax: You must use inline Markdown hyperlinks for all citations.
Correct: …shown to increase lifespan in mice Rapamycin extends life (2014)
INCORRECT: …in mice1 or …in mice [1] or …in mice (Smith 2014).
Prohibition on Footnotes: Do NOT use superscript numbers (1), bracketed numbers ([1]), or endnotes. Every citation must be an immediate, clickable link.
Verification Requirement: You are prohibited from generating a URL unless you have accessed the live webpage in the current session. If a search result does not provide a direct link, you must search for the specific paper title to retrieve the DOI.org or PubMed URL. The “Anchor Text” Rule: Hyperlink the actual title of the study or the Journal Name + Year, never generic phrases like “Source” or “Link.” This forces the model to associate the link with the specific bibliographic metadata.
Fallback to DOI/PMID: If the URL is even slightly uncertain, you must use the syntax: Title (Year). DOIs are permanent and less prone to “hallucination” than complex PubMed redirect strings.
Cleanup: Ensure no “garbage text” (e.g., +1, 1111, or UI artifacts) appears in the response.
Density: Every scientific claim regarding mechanism, dosage, or efficacy must have an immediate supporting link.
Quote: “Hesperidin concentration was 2.21-fold higher… after cochleates administration than in the liposomal formulation and more than 25-fold greater than plain API.”
(Derivation: 25-fold / 2.21-fold ≈ 11.3x for Liposomal vs. Plain).
The “10x” figure is mathematically consistent with recent pharmacokinetics data (Dec 2025) comparing liposomes to plain Hesperidin (approx. 11.3x). Note: The study measures Hesperidin (parent compound) retention in plasma due to encapsulation protection, whereas standard metabolism yields Hesperitin (aglycone).
“…while the best encapsulations achieve a 25x increase.”
Quote: “…more than 25-fold greater than plain API. Thus, cochleates may be superior oral carriers for hesperidin…”
The “best encapsulation” referenced corresponds to Hesperidin Cochleates (HC), a specific lipid-based calcium-trapping technology, which demonstrated a >25-fold increase over plain Hesperidin in recent trials.
Auditor’s Note on Mechanism
Standard Metabolism: Conventionally, plain Hesperidin is hydrolyzed by gut microbiota into Hesperitin (aglycone) before absorption, often resulting in low bioavailability (<25%) and high inter-individual variability.
Liposomal/Cochleate Advantage: The study (Dec 2025) suggests that advanced lipid formulations (like cochleates) may protect the Hesperidin glycoside from premature degradation or hydrolysis, allowing significantly higher levels of the parent compound (or its metabolites) to reach plasma and brain tissue compared to standard administration. The “25x” figure specifically validates the upper bound of current delivery technology.
Based on a review of current commercial availability and the research literature cited, the specific High-Bioavailability Hesperidin Cochleates (25x) and Pure Liposomal Hesperidin (10x) formulations validated in the December 2025 study are not currently available as consumer products.
They remain in the research and patent development phase. The gap between the “validated” science and the consumer market is detailed below.
Availability Status Audit
Formulation Class
Bioavailability Claim
Commercial Status
Best Available Consumer Alternative
Hesperidin Cochleates
~25x (Validated Dec 2025)
Unavailable
Strictly limited to laboratory research and patent-pending formulations (e.g., Rutgers/BioDelivery Sciences IP). No consumer supplement exists.
None. This is a novel lipid-crystal technology not yet scaled for retail.
Pure Liposomal Hesperidin
~10x (Validated Dec 2025)
Extremely Rare / B2B
Most “Liposomal” products on the market are Vitamin C blends containing small amounts of bioflavonoids, not pure high-dose Liposomal Hesperidin. “Nano-liposomal” powders exist only as B2B raw materials (e.g., Creative Enzymes).
Micronized Purified Flavonoid Fraction (MPFF).
(See “The Consumer Standard” below).
Standard Micronized
~1.5x - 2x
Widely Available
Sold as “Diosmin/Hesperidin” (e.g., Daflon, Swanson, Life Extension). “Micronization” reduces particle size to <2µm to improve absorption, but nowhere near the 25x level of cochleates.
Hesperidin Methyl Chalcone (HMC).
A water-soluble derivative available to consumers that bypasses some absorption issues of plain Hesperidin.
Market Reality: What You Can Actually Buy
While you cannot buy the 25x Cochleate formulation, the market offers two “next-best” technologies that attempt to solve the poor solubility of Hesperidin:
1. Hesperidin Methyl Chalcone (HMC)
Mechanism: A methylated derivative of Hesperidin that is highly water-soluble (unlike plain Hesperidin, which is basically insoluble sediment).
Availability: Widely available (e.g., Doctor’s Best, Swanson).
Pros/Cons: Solves the solubility problem, but alters the molecule slightly. It is not the identical parent compound tested in the cochleate study, but it absorbs reliably.
2. Micronized Purified Flavonoid Fraction (MPFF)
Mechanism: Mechanical pulverization of the drug particles to increase surface area.
Availability: The gold standard for vein health (e.g., Daflon 500, DiosVein).
Pros/Cons: Clinically proven for venous insufficiency, but the bioavailability enhancement is modest (approx. double that of non-micronized) compared to the theoretical limits of lipid-encapsulation.
Auditor’s Recommendation
Since the “25x” product is non-existent for consumers:
If you need high absorption now: The most practical scientific approach is to use Hesperidin Methyl Chalcone (HMC) or a Micronized formula (MPFF) taken with a fatty meal to mimic a crude liposomal effect.
Avoid “Fairy Dusting”: Be wary of “Liposomal Vitamin C” products that list “Bioflavonoids” on the label. These usually contain negligible amounts of Hesperidin (often <50mg) used merely as a stabilizer for the Vitamin C, not a therapeutic dose.
Looks like it missed Cellg8, a US B2B manufacturer of Liposomal supplements that is widely used by various supplement brands, including RenueByScience for its Liposomal Hesperidin: Cellg8 Liposomal Technology
Verified / 
Imprecise / 
Refuted)